Per policy, these drugs are exempt from USP <800> handling requirements under normal circumstances. The following outlines must be followed.
last updated: 06/02/2025
A generic (Brand) Route
abacavir (Ziagen) PO
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
300 mg tablet
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: do not crush tablet
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin , Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: malignant tumors observed in male/female mice/rats; genotoxic in in vivo micronucleus tests
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
1 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: do not crush tablet
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Handling/preparation PPE Requirements: Double CX gloves and gown
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: Repacking area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: do not crush tablet
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Wash skin with soap and water. Minimize dust accumulation.
C generic (Brand) Route
carBAMazepine (Carbatrol, TEGretol) PO
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
Bulk ⇒ Packager
Formulation(s):
100 mg Chew tablet (IDBH), 100 mg ER tablet (IMH)
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX glove and gown
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repacking area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for aplastic anemia, congenital malformations in offspring of mothers who took drug, rapid trans placental passage
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering. Risk associated when ingested.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves, gown. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management:
NIOSH Supplemental Information: MSHI
Reason for exemption of USP<800> Containment Requirements: Pregnancy Category C. MSHI recommends following NIOSH. Also notes, if cidofovir contacts the skin, wash membranes and flush thoroughly with water. Due to the mutagenic properties of cidofovir, adequate precautions including the use of appropriate safety equipment are recommended for the preparation, administration, and disposal of VISTIDE. NIOSH presently recommends that such agents be prepared in a Class II laminar flow biological safety cabinet and that personnel preparing drugs of this class wear surgical gloves and a closed front surgical-type gown with knit cuffs. Excess VISTIDE and all other materials used in the admixture preparation and administration should be placed in a leak-proof, puncture-proof container. The recommended method of disposal is high temperature incineration. Risks are related to systemic absorption.
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
Bulk ⇒ Packager
Formulation(s):
0.5 mg tablet, 1 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: Single CX glove Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: CSM
• Packaging/Reconstitution Location: Repackaging area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: minimal
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- Rx Destroyer Packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Increased risk of congenital abnormalities when taken in first trimester
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering.
colchicine (Colcrys, Mitigare) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
0.6 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: published animal reproduction and development studies indicate it causes embryo-fetal toxicity, teratogenicity and altered postnatal development at exposures within or above the clinical therapeutic range
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Handling/preparation PPE Requirements: Double CX glove and gown
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: Repackage area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: Swallow whole; do not crush or chew; do not open capsules.
Disposal / Spills
• Disposal of Drug Waste: Full - black bin , Trace - yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP
cycloSPORINE (Gengraf, Neoral, SandIMMUNE) PO
2024 NIOSH Table:
1A: Antineoplastic - IARC and NTP Classification
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
25 mg capsule, 100 mg capsule
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: do not open capsule
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
10 mg vaginal insert
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Freezer
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Double CX glove, gown. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: Do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin , Trace/packaging- trash
• Disposol of Used PPE: yellow bin
• Spill management: n/a
NIOSH Supplemental Information: Hazardous only for women in late pregnancy
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
dronedarone (Multaq) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
400 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: Do not handle while pregnant or trying to get pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Teratogenic in laboratory studies at 1/2 MRHD
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
0.5mg capsule
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration:
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Women warned not to handle
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk
estradiol (Estrace) PO
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
Bulk ⇒ Packager
Formulation(s):
1 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: Single CX glove, Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repackaging area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk
estradiol (Estrace, Estragyn) TOP
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
Bulk ⇒ Bulk
Formulation(s):
42 gram tube
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Double CX gloves
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk
• Handling/preparation PPE Requirements: Single CX glove Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repacking area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk
estrogens, conjugated (Premarin) IV
2024 NIOSH Table:
1A: Antineoplastic - IARC and NTP Classification
Packaging: Mfg ⇒ Dispense
n/a ⇒ n/a
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX glove, gown
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace/packaging- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: Wear CX gloves items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk. Listed by NTP and IARC. Not listed by OSHA. Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly.
Reason for exemption of USP<800> Containment Requirements: Pregnancy Category X. Risks are related to systemic absorption.
estrogens, esterified (Menest) PO
2024 NIOSH Table:
1: Antineoplastic
Packaging: Mfg ⇒ Dispense
Bulk ⇒ Packager
Formulation(s):
0.625 mg tablet
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: Single CX glove Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repacking area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
5 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX gloves Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: Do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Women should not handle crushed or broken finasteride tablets when they are pregnant or maybecome pregnant, due to potential risks to a male fetus
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
fluconazole (Diflucan) IV
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: Wear CX gloves items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: case reports describe congenital abnormalies in infants exposed in utero to maternal fluconazole (400-800mg/d) during most or all of the 1st trimester, similar to those seen in animal studies
Reason for exemption of USP<800> Containment Requirements: Preg Category C. Risks are related to systemic absorption. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap. This product does not contain any hazardous materials with occupational exposure.
fluconazole (Diflucan) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
100 mg tablet, 150 mg tablet, 200 mg tablet (IMH)
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration:
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: case reports describe congenital abnormalies in infants exposed in utero to maternal fluconazole (400-800mg/d) during most or all of the 1st trimester, similar to those seen in animal studies
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
fosphenytoin (Cerebyx) IV
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
n/a ⇒ [n/a]
Formulation(s):
100 mg injection, 500 mg injection
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX glove, gown
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Single CX glove, gown
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: Manage like antineoplastic agents
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP
Reason for exemption of USP<800> Containment Requirements: Preg Category D. No NIOSH requirements but is highest Group for carcinogen to humans; likely only by systemic absorption. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap. Per MSDS, "possible carcinogen"
G generic (Brand) Route
ganciclovir (Cytovene) IV
2024 NIOSH Table:
1: Antineoplastic
Packaging: Mfg ⇒ Dispense
n/a ⇒ n/a
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: moderate
• Handling/preparation PPE Requirements: Double CX gloves, gown, CSTD
• Receiving from Distributor: Designated area/ CX gloves
• Transport (dose is placed inside a plastic sealable bag): Transport container Single CX gloves
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Double CX gloves, gown, use of CSTD
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: Manage like antineoplastic agents
NIOSH Supplemental Information: in animal studies - carcinogenic, tetratogenic and caused aspermatogenesis; mfg instructions - handle according to guidelines issued for antineoplastic drugs
Reason for exemption of USP<800> Containment Requirements: Preg Category C. Avoid direct contact of the skin or mucous membranes with CYTOVENE-IV solutions. If such contact occurs, wash thoroughly with soap and water; rinse eyes thoroughly with plain water.
ganciclovir (Zirgan) OPTH
2024 NIOSH Table:
1: Antineoplastic
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
0.15% opthalmic gel
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Double CX gloves and gown
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: Swallow whole
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
NIOSH Supplemental Information: special warning on handling bottles and capsules
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Handling/preparation PPE Requirements: do not handle while pregnant; single CX gloves
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repacking area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Teratogenic in lab studies at 1/10 human dose,marked postnata lsurvival at 1/100 HD; severe liver injury reportedin patients; carcinogenicity observed at doses below HD
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering.
letrozole (Femara) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
2.5 mg tablet
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: do not crush tablet
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
M generic (Brand) Route
medroxyPROGESTERone (Depo-Provera) IM
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
Vial ⇒ Vial
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Double CX glove, gown. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace/packaging- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: Wear CX gloves; items used to clean up spill should be placed in a sealed bag and put in yellow bin
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form for dispensing, product is drawn up by nursing on unit, proper protections in place for administration
medroxyPROGESTERone (Provera) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
Bulk ⇒ Packager
Formulation(s):
5 mg tablet
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX glove Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repacking area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: IARC Group 2B
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering.
megestrol (Megace) PO
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
40 mg tablet, 40 mg soln cup
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Omnicell
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: Tablet crushed via RxCrush. Soln to be drawn up by nursing at bedside
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
NIOSH Supplemental Information: Breastfeeding should be discontinued if megestrol is required. Women at risk of pregnancy should avoid exposure.
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Handling/preparation PPE Requirements: Double CX glove and gown
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: Repacking area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: Done in Pharmacy
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Will comply with USP 800 recommendation for preparation
methIMAzole (Tapazole) PO
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
5mg tablet, 10 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: appears in human breast milk
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
methotrexate (Otrexup, Rasuvo, Rheumatrex, Trexall, Xatmep) PO
2024 NIOSH Table:
1: Antineoplastic
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
2.5 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: do not crush tablet
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
methotrexate (Trexall) IM
2024 NIOSH Table:
1: Antineoplastic
Packaging: Mfg ⇒ Dispense
Vial ⇒ [n/a]
Formulation(s):
50 mg/2 mL (2 mL)
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: moderate
• Handling/preparation PPE Requirements: Single CX glove, gown, and CSTD (as dosage form allows)
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous, Chemo zip locking bag
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: Required: Med Prep Area with Immediate Use Preparation standards
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Double bag Single CX gloves
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Double CX glove, gown
• Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: 1 vial per syringe - label accordingly
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: Wear CX gloves; items used to clean up spill should be placed in a sealed bag and put in yellow bin
Reason for exemption of USP<800> Containment Requirements: The act of drawing up an IM dose of methotrexate and giving it immediately is considered administration.
methylergonovine (Methergine) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
0.2 mg tablet
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
methylergonovine (Methergine) IM
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
Vial ⇒ Vial
Formulation(s):
0.2 mg vial
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Refrigerator
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Double CX glove, gown
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: Use Negative Pressue Technique when pulling up dose
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: yellow bin
• Spill management: Wear CX gloves; items used to clean up spill should be placed in a sealed bag and put in yellow bin
Reason for exemption of USP<800> Containment Requirements: Following USP 800 recommendations
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: if tablet is split, must add PPE of gown and mask
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. May cause infertility. May cause harm to unborn child.
• Handling/preparation PPE Requirements: do not handle while pregnant; single CX gloves
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: do not open capsule, do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for embry of fetal toxicity,malignancies,and serious infections,increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; Special Warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or directcontact with skin or mucous membranse of the powder contained in capsules and oral suspension. If such contact occurs,wash thoroughly with soap and water, rinse eyes with plain water
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
mycophenolate mofetil (Cellcept) PO
2024 NIOSH Table:
1: Antineoplastic
Packaging: Mfg ⇒ Dispense
BULK ⇒ UD
Formulation(s):
200 mg / mL suspension
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: do not handle while pregnant; single CX gloves, gown
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Packaging Area
• Packaging/Reconstitution Location: Repackage area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Done in Pharmacy
• Special Manipulation for Administration: do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- black bin , Trace/packaging- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: Wear CX gloves items used to clean up spill should be placed in a sealed bag and put in yellow bin
NIOSH Supplemental Information: BBW for embry of fetal toxicity,malignancies,and serious infections,increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; Special Warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or directcontact with skin or mucous membranse of the powder contained in capsules and oral suspension. If such contact occurs,wash thoroughly with soap and water, rinse eyes with plain water
mycophenolic acid (Myfortic) PO
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
Bulk ⇒ Packager
Formulation(s):
180 mg delayed release tablet
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX glove Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repackaging area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for first trimester pregnancy loss and increased risk of congenital malformations, BBW for lymphomas and other malignancies; genotoxic in vitro and in vivo
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Tumors observed in lab studies at 1/10 MRHD
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
Vial ⇒ [n/a]
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX gloves, gown
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin , Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: Wear CX gloves items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: Harzardous only of women in 3rd trimester
P generic (Brand) Route
pamidronate (Aredia) IV
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
n/a ⇒ [n/a]
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX glove, gown and CSTD. Do not prepare if pregnant.
• Receiving from Distributor: Standard
• Pharmacy Storage Area: IV area
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Single CX glove, gown
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: Do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: Wear CX gloves items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: Embryo-fetal toxicities at doses below recommended human doses
Reason for exemption of USP<800> Containment Requirements: Preg Category D. Impervious gloves and gown are recommended in MSDS.
PARoxetine (Paxil) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
10 mg tablet, 20 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: do not crush tablet
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin , Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Increased risk of congenital abnormalities when taken in first trimester; complications in pregnancy when taken in 3rd trimester
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Single CX glove, gown
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP
Reason for exemption of USP<800> Containment Requirements: Preg Category D. No NIOSH requirements but is highest Group for carcinogen to humans; likely only by systemic absorption. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap. Per MSDS, "possible carcinogen"
phenytoin (Dilantin, Phenytek) PO
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
50 mg tablet (IMH), 100 mg ER capsule, 100 mg/4 ml cup (IMH)
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace/packaging- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Handling/preparation PPE Requirements: Single CX glove; Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repackage area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: IARC Group 2b; NTP***
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Abortion and developmental abnormalities seen at low doses in lab studies, evidence of tumors at low doses
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for tumorogenicity in lab studies
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Increased risk of lymphomas and other malignancies; reproductive effectsseen in lab studiesbelowMRHD; excreted in breast milk
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
tamoxifen (Nolvadex, Soltamox) PO
2024 NIOSH Table:
1A: Antineoplastic - IARC and NTP Classification
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
10 mg tablet
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Designated area/ CX gloves
• Pharmacy Storage Area: Hazardous
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: Yes
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: yellow bin
• Spill management: n/a
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP***
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
7.5 mg capsule
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: CSM
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- Rx Destroyer Packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: increased risk of congenital malformationsassociated with treatment during 1st trimester
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
temazepam (Restoril) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
Bulk ⇒ UD
Formulation(s):
15 mg capsule
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: Single CX glove; Wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: CSM
• Packaging/Reconstitution Location: Repackage area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- Rx Destroyer Packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: increased risk of congenital malformationsassociated with treatment during 1st trimester
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering.
testosterone (Depo-T) IM
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
n/a ⇒ [n/a]
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: CSM
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- Rx Destroyer Packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: Wear CX gloves; items used to clean up spill should be placed in a sealed bag and put in purple bin
NIOSH Supplemental Information: Children should avoid contact with unwashed or unclothed application sites on skin
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
100 mg tablet
Stock @ IDBH?
Y
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: Not recommended to crush, break or chew
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: Do not break or crush
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
valproic acid (Depacon) IV
2024 NIOSH Table:
2: Non - Antineoplastic
Packaging: Mfg ⇒ Dispense
n/a ⇒ [n/a]
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: Single CX glove, gown
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species
Reason for exemption of USP<800> Containment Requirements: Preg Category D. Risks are related to systemic absorption. Skin contact - wash immediately with soap and water.
valproic acid (Depakene, Depakote) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
125 mg EC tablet (IDBH), 250 mg ER tablet (IDBH), 250 mg EC tablet (IDBH), 500 mg ER tablet, 250 mg capsule, 125 mg sprinkle, 250 mg/5 mL cup
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for teratogenicity; congenital malformations, including neural tube defects; teratogenic in muliple species
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Preg Category D. Release to the environment should be minimized per MSDS.
voriconazole (Vfend) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
200 mg tablet
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
W generic (Brand) Route
warfarin (Coumadin, Jantoven) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: via Mouth- Single pair of CX approved gloves via Tube- double CX gloves and gown Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
20 mg capsule, 60 mg capsule (IDBH)
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: Swallow whole
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups borndead and a decrease in postnatal survival at less than MRHD
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
ziprasidone (Geodon) IM
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
n/a ⇒ [n/a]
Formulation(s):
20 mg/mL powder
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: low
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: Wear CX gloves; items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups borndead and a decrease in postnatal survival at less than MRHD
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form for dispensing, product is drawn up by nursing on unit, proper protections in place for administration. Wash off immediately with plenty of water for at least 15 minutes. *This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
n/a ⇒ [n/a]
Formulation(s):
Ready to hang
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimial
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: Do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Number of stillbirths increased and survival of neonates decreased in lab studies at low doses
Reason for exemption of USP<800> Containment Requirements: Preg Category D. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap.
zoledronic acid (Zometa) IV
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
n/a ⇒ [n/a]
Formulation(s):
Stock @ IDBH?
No
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: moderate
• Handling/preparation PPE Requirements: Single CX glove and gown Do not prepare if pregnant.
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: moderate
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: n/a
• Special Manipulation for Administration: Do not handle while pregnant
Disposal / Spills
• Disposal of Drug Waste: Full- black bin Trace- yellow bin
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Number of stillbirths increased and survival of neonates decreased in lab studies at low doses
Reason for exemption of USP<800> Containment Requirements: Preg Category D. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap.
zonisamide (Zonegran) PO
2024 NIOSH Table:
2B: Non-antineoplastic - Only Developmental and/or Reproductive Risk
Packaging: Mfg ⇒ Dispense
UD ⇒ UD
Formulation(s):
100 mg capsule
Stock @ IDBH?
Yes
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: Yes
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration
Exposure Risk: low
• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: Do not handle while pregnant. Swallow whole.
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: Teratogenic in multiple miscellaneous animal studies
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
Add Formweb to your mobile device